Regulation & law · 16/11/2015Updated: 10/17/2026 · 1 min read
National Cancer Institute Grants Exclusive Patent License for Cancer Detection Tests
Summary
The National Cancer Institute is proposing a modification to its previous notice regarding the grant of an exclusive patent license to practice the inventions embodied in U.S. Patents and Patent Applications, to Beacon Biomedical, Inc., a company based in Scottsdale, AZ, USA, for the development of Cripto-1 Point of Care (POC) tests and kits for cancer detection.
Original source language: Federal Register — All DocumentsOpen original release →